Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor

Journal of Cellular Biochemistry

Volumn 93, Issue 1, 2004, Pages 120-132

  Huckle, William R ^a   Roche, Rebecca I ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

Flt 1; Receptor; RNA processing; Vascular endothelial growth factor

Indexed keywords

COMPLEMENTARY DNA; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN SFLT 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; POLYADENYLIC ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

3' UNTRANSLATED REGION; AMINO ACID SEQUENCE; ARTICLE; GENE AMPLIFICATION; GENE LIBRARY; INTRON; MOLECULAR CLONING; POLYADENYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; RNA PROCESSING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ALTERNATIVE RNA SPLICING; ANIMAL; BACTERIAL ARTIFICIAL CHROMOSOME; C57BL MOUSE; DRUG ANTAGONISM; GENE DELETION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; POINT MUTATION;

3' UNTRANSLATED REGIONS; ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CLONING, MOLECULAR; INTRONS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; POINT MUTATION; POLY A; POLYMERASE CHAIN REACTION; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; SEQUENCE DELETION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 16644363520     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20142     Document Type: Article

References (50)

1. Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marme D, Martiny-Baron G. 1997. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 272:10382-10388.
2. Beaudoing E, Freier S, Wyatt JR, Claverie JM, Gautheret D. 2000. Patterns of variant polyadenylation signal usage in human genes. Genome Res 10:1001-1010.
3. Carmeliet P. 2003. Angiogenesis in health and disease. Nat Med 9:653-660.
4. Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. 2001. Effect of human recombinant vascular endothelial growth factor-165 on progression of atherosclerotic plaque. J Am Coll Cardiol 37:2126-2130.
5. Chen F, MacDonald CC, Wilusz J. 1995. Cleavage site determinants in the mammalian polyadenylation signal. Nucleic Acids Res 23:2614-2620.
6. Choi K, Wall C, Hanratty R, Keller G. 1994. Isolation of a gene encoding a novel receptor tyrosine kinase from differentiated embryonic stem cells. Oncogene 9:1261-1266.
7. Chou ZF, Chen F, Wilusz J. 1994. Sequence and position requirements for uridylate-rich downstream elements of polyadenylation signals. Nucleic Acids Res 22:2525-25231.
8. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS. 1998. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 59:1540-1548.
9. Conne B, Stutz A, Vassalli JD. 2000. The 3′ untranslated region of messenger RNA: A molecular 'hotspot' for pathology? Nat Med 6:637-641.
10. Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, Claffey KP. 1997. Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 108:263-268.
11. Epstein SE, Fuchs S, Zhou YF, Baffour R, Kornowski R. 2001. Therapeutic interventions for enhancing collateral development by administration of growth factors: Basic principles, early results and potential hazards. Cardiovasc Res 49:532-542.
12. Finnerty H, Kelleher K, Morris GE, Bean K, Merberg DM, Kriz R, Morris JC, Sookdeo H, Turner KJ, Wood CR. 1993. Molecular cloning of murine FLT and FLT4. Oncogene 8:2293-2298.
13. Folkman J. 2001. Angiogenesis-dependent diseases. Semin Oncol 28:536-542.
14. Frohman MA, Dush MK, Martin GR. 1988. Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer. Proc Natl Acad Sci USA 85:8998-9002.
15. Gerber HP, Ferrara N. 2003. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 81:20-31.
16. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT. 1998. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95:8795-8800.
17. Graber JH, Cantor CR, Mohr SC, Smith TF. 1999. In silico detection of control signals: mRNA 3′-end-processing sequences in diverse species. Proc Natl Acad Sci USA 96:14055-14060.
18. Graubert MD, Ortega MA, Kessel B, Mortola JF, Iruela-Arispe ML. 2001. Vascular repair after menstruation involves regulation of vascular endothelial growth factor-receptor phosphorylation by sFLT-1. Am J Pathol 158:1399-1410.
19. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. 1999. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 13:537-545.
20. Huckle WR, Roche RI. 2001. Regulation of expression of sFlt-1, an endogenous inhibitor of VEGF-stimulated angiogenesis. Mol Biol Cell 12(Suppl):229a-230a.
21. Ishii TM, Zerr P, Xia XM, Bond CT, Maylie J, Adelman JP. 1998. Site-directed mutagenesis. Methods Enzymol 293:53-71.
22. Kendall RL, Thomas KA. 1993. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705-10709.
23. Kendall RL, Wang G, Thomas KA. 1996. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226:324-328.
24. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844.
25. Kondo K, Hiratsuka S, Subbalakshmi E, Matsushime H, Shibuya M. 1998. Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene 208:297-300.
26. Kong HL, Hecht D, Song W, Kovesdi I, Hackett NR, Yayon A, Crystal RG. 1998. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9:823-833.
27. Krussel JS, Casan EM, Raga F, Hirchenhain J, Wen Y, Huang HY, Bielfeld P, Polan ML. 1999. Expression of mRNA for vascular endothelial growth factor transmembraneous receptors Flt1 and KDR, and the soluble receptor sflt in cycling human endometrium. Mol Hum Reprod 5:452-458.
28. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. 1996. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 270:H1803-H1811.
29. -Delta Delta C(T) method. Methods 25:402-408.
30. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K. 1995. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 4:357-362.
31. Los M, Voest EE. 2001. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin Oncol 28:93-105.
32. Mezquita J, Mezquita B, Pau M, Mezquita C. 2003. Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262. J Cell Biochem 89:1138-1147.
33. Nguyen LL, D'Amore PA. 2001. Cellular interactions in vascular growth and differentiation. Int Rev Cytol 204:1-48.
34. Osoegawa K, Tateno M, Woon PY, Frengen E, Mammoser AG, Catanese JJ, Hayashizaki Y, deJong PJ. 2000. Bacterial artificial chromosome libraries for mouse sequencing and functional analysis. Genome Res 10:116-128.
35. Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pilot PA, Tressler RJ, Cushman C, Reynolds MA, Parry TJ. 2000. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 6:2094-2103.
36. Peterson ML. 1992. Balanced efficiencies of splicing and cleavage-polyadenylation are required for mu-s and mu-m mRNA regulation. Gene Expr 2:319-327.
37. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ. 1999. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209-5218.
38. Reed R, Palandjian L. 1997. Spliceosome assembly. In: Krainer AR, editor. Eukaryotic mRNA processing. Oxford: IRL Press, pp 103-129.
39. Shawver LK, Lipson KE, Fong TAT, McMahon G, Plowman GD, Strawn LM. 1997. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Dev Today 2:50-63.
40. Sheets MD, Ogg SC, Wickens MP. 1990. Point mutations in AAUAAA and the poly (A) addition site: Effects on the accuracy and efficiency of cleavage and polyadenylation in vitro. Nucleic Acids Res 18:5799-5805.
41. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. 1990. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5:519-524.
42. Shiose S, Sakamoto T, Yoshikawa H, Hata Y, Kawano Y, Ishibashi T, Inomata H, Takayama K, Ueno H. 2000. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid-malignant melanoma. Invest Ophthalmol Vis Sci 41:2395-2403.
43. Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marme D, Martiny-Baron G. 1999. Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 59:3185-3191.
44. Spranger J, Pfeiffer AF. 2001. New concepts in pathogenesis and treatment of diabetic retinopathy. Exp Clin Endocrinol Diabetes 109:S438-S450.
45. Takagaki Y, Seipelt RL, Peterson ML, Manley JL. 1996. The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation. Cell 87:941-952.
46. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Kara N. 2000. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 60:2169-2177.
47. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. 1994. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995.
48. Yamane A, Seetharam L, Yamaguchi S, Gotoh N, Takahashi T, Neufeld G, Shibuya M. 1994. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Fit tyrosine kinase receptor family (Fit-1 and KDR/FIk-1). Oncogene 9:2683-2690.
49. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.
50. Zhao J, Hyman L, Moore C. 1999. Formation of mRNA 3′ ends in eukaryotes: Mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol Mol Biol Rev 63:405-445.